Allarity Therapeutics, Inc.
ALLR
$1.61
-$0.15-8.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.96% | -70.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.13% | -58.51% | |||
| Operating Income | -36.13% | 58.51% | |||
| Income Before Tax | 15.08% | 63.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.08% | 63.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.08% | 63.34% | |||
| EBIT | -36.13% | 58.51% | |||
| EBITDA | -36.23% | 58.65% | |||
| EPS Basic | 39.09% | 85.76% | |||
| Normalized Basic EPS | 39.10% | 85.76% | |||
| EPS Diluted | 39.09% | 85.76% | |||
| Normalized Diluted EPS | 39.10% | 85.76% | |||
| Average Basic Shares Outstanding | 39.44% | 157.36% | |||
| Average Diluted Shares Outstanding | 39.44% | 157.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||